Asher Mullard

Science Journalist

Writing about drugs, biotech, the pharmaceutical industry, health and more.

Asher Mullard

Science Journalist

Writing about drugs, biotech, the pharmaceutical industry, health and more.

CAR-T therapy for multiple sclerosis enters US trials for first time
Could engineered immune cells halt the progression of a degenerative autoimmune disorder?
Nature
Landmark Alzheimer’s drug approval confounds research community
Many scientists say there is not enough evidence that Biogen’s aducanumab is effective.
Nature
The quest to prevent MS
Some people develop multiple sclerosis after an infection. Could a vaccine prevent that?
Nature
The COVID antibody enigma
Antibody drugs have gained little traction in infectious diseases. Could COVID change that?
Nature
Half of top cancer studies fail high-profile reproducibility effort
Barriers to reproducing preclinical results included unhelpful author communication.
Nature
Targeted protein degraders crowd into the clinic
15 targeted degraders should be in the clinic by the end of 2021.
Nature Reviews Drug Discovery
FDA approves 100th antibody
Antibodies now account for nearly a fifth of the agency’s new drug approvals each year.
Nature Reviews Drug Discovery
On the hunt for monomeric degraders
Simple small molecules that break down proteins may be more common than you think.
C&EN
COVID-19 vaccine development pipeline gears up
Vaccine makers have advanced ten COVID-19 vaccine candidates into clinical trials.
The Lancet
First targeted protein degrader hits the clinic
New drugs that harness cellular machinery to degrade targets are entering clinical trials.
Nature Reviews Drug Discovery
The drug-maker's guide to the galaxy
Machine learning is helping chemists search the vast chemical universe for better medicines.
Nature
Immunotherapies move beyond cancer, with first foray into sepsis
Could cutting-edge cancer drugs beat back deadly infections of the blood?
Boston Globe/STAT
Anti-inflammatory gets long awaited test as an antidepressant
J&J is testing a radical new approach to depression — by dialing down inflammation in the body.
Boston Globe/STAT
Run, forest, run
How to move a forest (before climate change kills it).
The Walrus
Tinker, bacteria, eukaryote, spy
Bacteria and their hosts spy on one another, intercepting chemical communications.
Nature
Fat busters: Are diet pills an impossible dream?
The next generation of weight-loss drugs is on its way. Will their side effects be hard to swallow?
New Scientist

About

Asher Mullard

I am a journalist, covering the science and business of biological discoveries and emerging drugs. I have written for Nature, The Lancet, The Boston Globe, The New Scientist, The Walrus and many others.

My article 'Run, Forest, Run' received Honorary Mention in the National Magazine Awards.

I am a contributing editor for Nature Reviews Drug Discovery.

Please email me at ashermullard@gmail.com.